Artivion Announces Strong Q2 2026 Financial Results with Revenue Growth and New Product Approval

Artivion Unveils Impressive Financial Results for Second Quarter 2026

Atlanta, August 6, 2026 - Artivion, Inc. (NYSE: AORT), a recognized leader in cardiac and vascular surgical innovations, today declared its financial outcomes for the second quarter ended June 30, 2026, reflective of a notable upward trend.

Revenue Growth and Product Demand

Artivion achieved a remarkable revenue of $125.8 million during the second quarter of 2026, marking an 11% increase from $113 million recorded in the same period last year. This growth was predominantly attributable to the expanding sales of their On-X mechanical heart valves, which experienced an 18% increase, and stent grafts, which climbed by 12%, both measured on a constant currency basis. Pat Mackin, the Chairman and CEO, expressed satisfaction with this upward trend, emphasizing that the revenue increase is rooted in robust product demand and strategic execution.

Aside from revenue growth, Artivion also reported a 7% increase in adjusted EBITDA, reaching $26.4 million. Despite a net loss of $13.5 million, the company announced a non-GAAP net income of $6.3 million, equating to $0.13 per diluted share, showcasing resilience in the face of market challenges.

Regulatory Approvals and Acquisitions

In a significant milestone, Artivion was granted FDA PMA approval for its AMDS Hybrid Prosthesis, further solidifying its leadership in the aortic arch market. The AMDS, combined with their existing ARCEVO LSA and the newly acquired NEXUS Aortic Arch Stent Graft System from Endospan Ltd., positions Artivion as the only company worldwide to provide a comprehensive aortic arch solutions portfolio.

Mackin stated, "The AMDS approval and our acquisition of Endospan and its innovative technologies demonstrate our commitment to expanding our market-leading product offerings in aortic disease management. These achievements are expected to enhance our capabilities and drive long-term growth."

The integration of Endospan’s technology is poised to contribute to Artivion’s extensive pipeline, which anticipates introducing three additional PMA programs in the near future.

Strong Outlook for 2026

Looking ahead, the company reaffirmed its revenue expectations of $480 million to $496 million for the full year 2026, translating to an anticipated growth rate of 7% to 11% on an adjusted constant currency basis, compared to 2025 revenue levels. Artivion expects its adjusted EBITDA for the year to fall between $92 million and $99 million, despite incurring around $8 million in expenses related to the Endospan acquisition.

The company also noted that favorable currency conditions might present a tailwind, enhancing their revenue performance beyond current forecasts.

Conclusion

With a robust financial performance in Q2 2026, highlighted by significant revenue growth and strategic regulatory milestones, Artivion is well-positioned for sustained success in the cardiovascular medical device market. Its concentrated efforts on expanding its product portfolio and strategic acquisitions reflect a strong trajectory for long-term success in addressing complex cardiovascular challenges globally.

For ongoing updates and details, stakeholders are encouraged to follow Artivion’s future business developments, including the upcoming live virtual conference scheduled for August 6, 2026. Investors can find further details on their official website www.Artivion.com.